Literature DB >> 3090040

Binding of plasminogen to extracellular matrix.

B S Knudsen, R L Silverstein, L L Leung, P C Harpel, R L Nachman.   

Abstract

We have previously demonstrated that plasminogen immobilized on various surfaces forms a substrate for efficient conversion to plasmin by tissue plasminogen activator (t-PA) (Silverstein, R. L., Nachman, R. L., Leung, L. L. K., and Harpel, R. C. (1985) J. Biol. Chem. 260, 10346-10352). We now report the binding of human plasminogen to the extracellular matrix synthesized in vitro by cultured endothelial cell monolayers. The binding was specific, saturable at plasma plasminogen concentrations, reversible, and lysine-binding site-dependent. Functional studies demonstrated that matrix immobilized plasminogen was a much better substrate for t-PA than was fluid phase plasminogen as shown by a 100-fold decrease in Km. Activation of plasminogen by t-PA and urokinase on the matrix was equally efficient. The plasmin generated on the matrix, in marked contrast to fluid phase, was protected from its fast-acting inhibitor, alpha 2-plasmin inhibitor. Matrix-associated plasmin converted bound Glu- into Lys-plasminogen, which in turn is more rapidly activated to plasmin by t-PA. The extracellular matrix not only binds and localizes plasminogen but also improves plasminogen activation kinetics and prolongs plasmin activity in the subendothelial microenvironment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090040

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

Authors:  M S Stack; S Gately; L M Bafetti; J J Enghild; G A Soff
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Rapid neural regulation of muscle urokinase-like plasminogen activator as defined by nerve crush.

Authors:  D Hantaï; J S Rao; B W Festoff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

3.  Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9.

Authors:  M G Martínez-Hernández; L A Baiza-Gutman; A Castillo-Trápala; D Randall Armant
Journal:  Reproduction       Date:  2010-11-12       Impact factor: 3.906

4.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.

Authors:  E Levi; R Fridman; H Q Miao; Y S Ma; A Yayon; I Vlodavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

5.  Binding of human plasminogen to basement-membrane (type IV) collagen.

Authors:  M S Stack; T L Moser; S V Pizzo
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

6.  Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.

Authors:  G H Gibbons; R E Pratt; V J Dzau
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

7.  Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.

Authors:  B S Knudsen; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

8.  The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate.

Authors:  Y Okada; E D Harris; H Nagase
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

9.  Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.

Authors:  J Reinartz; H Näher; H Mai; M D Kramer
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

10.  Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary atherosclerotic lesions involved in acute myocardial infarction.

Authors:  K Yorimitsu; T Saito; T Toyozaki; T Ishide; N Ohnuma; Y Inagaki
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.